Status:
RECRUITING
Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
Lead Sponsor:
Centre Francois Baclesse
Conditions:
Triple Negative Breast Cancer
Organoid
Eligibility:
FEMALE
18+ years
Brief Summary
Initially described in 2009 on LGR5 positive stem cells from intestine, organoids correspond to a 3D cell culture that preserves the organization and part of the initial function of the organ from whi...
Eligibility Criteria
Inclusion
- Patient over 18 years of age
- Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapy
- Patient affiliated to a social security system
- Proficiency in French language,
- Patient having signed the consent to participate in the study.
Exclusion
- Pregnant women
- Persons deprived of liberty or under guardianship (including curatorship)
- History of any other clinically active malignancy in the last 5 years prior to inclusion
Key Trial Info
Start Date :
January 9 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT05404321
Start Date
January 9 2023
End Date
December 1 2026
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse
Caen, France, 14076